Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 8/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20329029 | 0.75 | PDCD1 (0.47) | PDCD1CD274ALDH1A1NPC1MAPT | |
| SCHEMBL20324274 | 0.71 | PDCD1 (0.66) | PDCD1CD274IDO1 | |
| SCHEMBL20295946 | 0.69 | PDCD1 (0.51) | PDCD1CD274HTR2CCNR2 | |
| SCHEMBL20296251 | 0.69 | GRM5 (0.47) | PDCD1CD274HTR2C | |
| SCHEMBL31711064 | 0.66 | HTR2C (0.45) | PDCD1CD274HTR2CNPC1RAB9A | |
| SCHEMBL20294344 | 0.64 | PDCD1 (0.43) | PDCD1CD274HTR2CNPC1RAB9A | |
| SCHEMBL30145307 | 0.64 | PDCD1 (0.43) | PDCD1CD274HTR2CNPC1RAB9A | |
| SCHEMBL19569144 | 0.63 | DCK (0.36) | HTR2CIDO1ALDH1A1NPC1MAPT | |
| SCHEMBL30836868 | 0.62 | MAOB (0.38) | — | |
| SCHEMBL10336938 | 0.61 | CTSA (0.45) | IDO1ALDH1A1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339149-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2022-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339149-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | PDCD1 157/4885CD274 88/4885HTR2C 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.